The effect of 2-h infusion of 2-chlorodeoxyadenosine (Cladribine) with prednisone in previously untreated B-cell chronic lymphocytic leukaemia

European Journal of Cancer

Volumn 33, Issue 14, 1997, Pages 2347-2351

  Robak, T ^a   Blasinska Morawiec M ^a   Blonski J Z ^a   Krykowski, E ^a   Komarnicki, M ^b   Trepinska E ^b   Kazmierczuk M ^b   Hansz, J ^b   Dmoszynska A ^c   Rolinski J ^c   Konopka, L ^d   Skotnicki, A B ^e   Nowak, W S ^e   Kotlarek Haus, S ^f   Zdziarska, B ^g   Urasinski I ^g  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^d INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^e JAGIELLONIAN UNIVERSITY   (Poland)

^f Academy of Medicine   (Poland)

^g POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

2 chlorodeoxyadenosine; Chronic lymphocytic leukaemia; Efficiency; First line therapy; Prednisone; Side effects

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CLADRIBINE; PREDNISONE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INFUSION; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SKIN ALLERGY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLADRIBINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, B-CELL, CHRONIC; MALE; MIDDLE AGED; PREDNISONE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0344783802     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00349-3     Document Type: Article

References (32)

1. Carson DA, Wasson DB, Lamon J, Beutler E. A potent new anti-lymphocyte agent: 2-chlorodeoxyadenosine. Abstr. no 568. Blood. 60:(Suppl. 1):1982;160a.
2. Kazimierczuk Z, Cottam HB, Ravanliar GR, Robins RK. Synthesis 2′-deoxytubercidin, 2′-deoxyadenosin and related 2′-deoxynucleosides via a novel direct stereospecific serum salt glycosylation procedure. J Am Chem Soc. 106:1984;6379-6382.
3. Carson DA, Wasson DB, Teatle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood. 62:1983;737-743.
4. Beutler E. Drug profile: Cladribine (2-chlorodeoxyadenosine). Lancet. 340:1992;952-956.
5. Carrera CJ, Saven A, Piro LD. Purine metabolism of lymphocytes. Hematol Oncol Clin N Am. 8:1994;357-381.
6. Robak T. Cladribine (2-chlorodeoxyadenosine) in the treatment of haematologic malignancies. Appl Biol Commun. 6:(Suppl. 1):1996;75-90.
7. Warzocha K, Fabianowska-Majewska K, Błoński JZ, Krykowski E, Robak T. 2-chlorodeoxyadenosine inhibits activity of adenosine deaminase and S-adenosylhomocysteine hydrolase in patients with chronic lymphocytic leukemia. Eur J Cancer. 33:1997;170-173.
8. Piro LD, Carrera CJ, Beutler G, Carson DA. 2-chlorodeoxyadenosine is an effective new agent for the treatment of chronic lymphocytic leukemia. Blood. 72:1988;1069-1073.
9. Juliusson G, Liliemark J. High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol. 11:1993;679-689.
10. Robak T, Błasińska-Morawiec M, Krykowski E, et al. Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymph 1996b, 22, 509-514.
11. Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk Lymph. 5:(Suppl. 1):1991;133-138.
12. Saven A, Lemon RH, Kosty M, Beutler E, Piro LD. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukaemia. J Clin Oncol. 13:1995;570-574.
13. Delannoy A, Martiat P, Gala JL, et al. 2-Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL). Leukemia 1995, 9, 1130-1135.
14. Cheson BD, Bennett JM, Rai KR, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute sponsored Working Group. Am J Hematol 1988, 29, 152-163.
15. Rai KR, Savitsky A, Cronkite EP, Channa AD, Levy R, Pasternack B. Clinical staging of chronic lymphocytic leukemia. Blood. 46:1975;219-234.
16. Robertson LE, Huh YO, Beutler JJ, et al. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood 1992, 80, 29-36.
17. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5, 649-655.
18. Beutler E, Piro LD, Saven A, Kay AC, McMillian R, Longmire R. 2-Chlorodeoxyadenosine (2-CdA): A potent chemotherapeutic and immunosuppressive nucleoside. Leuk Lymph. 5:1991;1-8.
19. Tallman MS, Hakimian D, Zanzig C, et al. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 1995, 13, 983-988.
20. Juliusson G, Liliemark J. Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia. Ann Oncol. 7:1996;373-379.
21. Cheson BD. Current approaches to the chemotherapy of B-cell chronic lymphocytic leukaemia: A review. Am J Hematol. 32:1989;72-77.
22. Han T, Ezdinli EZ, Shimaoka K, Desai D. Chlorambucil vs combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukaemia. Cancer. 31:1973;502-508.
23. Keating MJ. Treatment of chronic lymphocytic leukaemia. In Freireich EJ, Kantarijan H, eds. Therapy of Hematopoietic Neoplasia. New York, Marcel Dekker, 1991, 175.
24. Savitsky A, Rai KR, Glidevell O, Silver RT, Cancer and Leukemia Group B. Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood. 50:1997;1049-1059.
25. O'Brien S, Kantarijan H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993, 82, 1695-1700.
26. + lymphocyte counts in patients with hairy cell leukemia. Blood. 83:1994;2906-2911.
27. Robak T, Błasińska-Morawiec M, Krykowski E, et al. 2-Chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk Lymph 1996a, 22, 107-111.
28. Liliemark J, Juliusson G. Cellular pharmacokinetics of 2-chloro-2′-deoxyadenosine nucleotides: Comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemic patients. Clin Cancer Res. 1:1995;385-390.
29. Dimopoulos ME, Kantarijan H, Esty E, et al. Treatment of Waldenström macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 1993, 118, 195-198.
30. Robak T, Błasińska-Morawiec M, Krykowski E. Transient eosinophilia in a patient with hairy-cell leukaemia treated with 2-chlorodeoxyadenosine. Acta Haematol Pol. 23:1992;285-290.
31. Anaisse E, Kontogiannio DP, Kantarijan H, Elting L, Robertson LE, Keating M. Listeriosis in patients with chronic lymphocytic leukaemia who were treated with fludarabine and prednisone. Ann Intern Med. 117:1992;466-469.
32. Carrera CJ, Tarai C, Lotz M, et al. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo: a novel approach to immunosuppressive therapy. J Clin Invest 1990, 86, 1480-1488.